title: A retrospective study of the influence of the vitreomacular interface on macular oedema secondary to retinal vein occlusion.
abstract: To compare anti-vascular endothelial growth factor (VEGF) treatment outcomes for macular oedema (ME) secondary to retinal vein occlusion (RVO) based on vitreoretinal interface (VRI) status.
  
  
  
  This retrospective case series includes treatment-naive eyes diagnosed with RVO and treated with anti-VEGF injections. Eyes were stratified based on international VRI classification schema at baseline into three groups-vitreomacular traction (group A), no posterior vitreous detachment (PVD) (group B) and PVD without vitreomacular attachment (group C). Fifty-two eyes were identified based on inclusion/exclusion criteria. The primary endpoint was change in central subfield thickness (CST) on optical coherence tomography at 6 months.
  
  
  
  There were no statistically significant differences in baseline characteristics of patients with RVO when stratified by VRI subgroups. After 6 months of treatment, there was no statistically significant difference in the change in CST from baseline between VRI cohorts (p=0.11). There was a trend demonstrating the greatest improvement in CST in eyes in group A compared with eyes in groups B and C (-224.13 μm, -160.88 μm and -50.92 μm, respectively, p=0.11 between cohorts). Mean change in logarithm of the minimum angle of resolution visual acuity from baseline to month 6 in group A compared with groups B and C was -0.25, -0.14 and -0.13, respectively (p=0.64 between cohorts).
  
  
  
  We did not identify an association between VRI status and treatment outcomes with anti-VEGF agents for ME secondary to RVO.
authors.affiliation: Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA.
authors.forename: Rishi P
authors.initials: RP
authors.lastname: Singh
authors.affiliation: Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA.
authors.forename: Karishma A
authors.initials: KA
authors.lastname: Habbu
authors.affiliation: Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA.
authors.forename: Rumneek
authors.initials: R
authors.lastname: Bedi
authors.affiliation: Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA.
authors.forename: Fabiana Q
authors.initials: FQ
authors.lastname: Silva
authors.affiliation: Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA.
authors.forename: Justis P
authors.initials: JP
authors.lastname: Ehlers
authors.affiliation: Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA.
authors.forename: Andrew P
authors.initials: AP
authors.lastname: Schachat
authors.affiliation: Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA.
authors.forename: Jonathan E
authors.initials: JE
authors.lastname: Sears
authors.affiliation: Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA.
authors.forename: Sunil K
authors.initials: SK
authors.lastname: Srivastava
authors.affiliation: Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA.
authors.forename: Peter K
authors.initials: PK
authors.lastname: Kaiser
authors.affiliation: Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA.
authors.forename: Alex
authors.initials: A
authors.lastname: Yuan
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D012170:Retinal Vein Occlusion / Q000150:complications / Q000188:drug therapy*; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D020255:Vitreous Detachment / Q000209:etiology*
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A
keywords: Macula; Retina; Vitreous